REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Options

1 Oct 2012 07:00

RNS Number : 5255N
Sopheon PLC
01 October 2012
 



FOR IMMEDIATE RELEASE

1 October 2012

 

SOPHEON PLC

 

GRANT OF OPTIONS

 

Sopheon plc ("Sopheon" or " the Company") announces that it has granted options over ordinary shares of 5 pence each in the share capital of the Company ("Ordinary Shares") to certain directors. These grants are part of a wider grant of options over 5,285,598 Ordinary Shares, to both new and existing staff members.

 

Of this total, options over 285,000 Ordinary Shares have been granted to new members of staff. The remaining 5,000,598 have been granted to members of staff that have been with the company for ten years or longer. This second category represents the replacement of options previously granted to these members of staff approximately ten years ago, of which 146,112 lapsed in 2011 and 4,854,486 have lapsed in 2012 or are due to lapse in 2013. As part of this event, the options due to lapse in 2013 have been cancelled. Accordingly, the vast majority of this category can be considered as replacement or continuation of options in existence at December 31, 2011 and included in our financial statements as of that date.

 

Four directors are involved in this event. Barry Mence has been granted options over 122,500 ordinary shares, Andrew Michuda over 2,767,594, Arif Karimjee over 462,500 and Bernard Al over 25,000 ordinary shares. Following this grant, Barry Mence has options over a total of 485,000 ordinary shares, Andrew Michuda over 3,997,000, Arif Karimjee over 1,150,000 and Bernard Al over 25,000 ordinary shares.

 

All the options will vest evenly over 3 years, and are exercisable up to 10 years from the date of grant. The options have been granted at a price of 5.25 pence per share, being the mid-market closing price on AIM on 28 September 2012.

 

Chairman Barry Mence said:

 

"We are proud of the fact that we have so many staff that have been with us for ten years or longer, and have shown such commitment to our company and our vision. It is right that share option incentives which are due to lapse without exercise are renewed, with vesting conditions designed to encourage continued commitment to the company."

 

For further information contact:

 

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Henrik Persson / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Guy McDougall / Heather Armstrong

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

About Sopheon

Sopheon (LSE: SPE) is an international provider of software and services. Sopheon's solutions structure, align and manage innovation processes to help organizations generate more revenues and profits from new products. Sopheon's solutions are used by industry leaders throughout the world, including BASF, Corning, Electrolux, Honeywell, Lockheed Martin, Philips and SABMiller. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Euronext in the Netherlands. For more information, please visit www.sopheon.com. 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEAXNPAEEAEFF
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.